BTK and B-cell chronic lymphocytic leukemia: In heavily pretreated relapsed/refractory chronic lymphocytic leukemia (CLL) patients, NX-2127 achieved >90% sustained BTK degradation with clinically meaningful responses in 67% (4/6) of patients, including partial responses in those harboring BTK-C481S mutations.